Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
William J. Burman(Case Western Reserve University), Richard E. Chaisson(Johns Hopkins University), Grace Muzanye(Case Western Reserve University), Charles L. Daley(National Jewish Health), John L. Johnson(University School), Sonal S. Munsiff(University of Rochester), Andrew Vernon(The University of Texas at El Paso), Melissa Engle(The University of Texas at San Antonio Health Science Center), Ann Mosher(Case Western Reserve University), Zhen Zhao(Cornell University), Shurjeel Choudhri(Case Western Reserve University), Stefan Goldberg
Cited by 285
Related Papers
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
|PubMed|2010|1.1k
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
|European Respiratory Journal|2020|876
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
|Clinical Infectious Diseases|2020|828